Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
————————————
Panelists
Ahmed Obeidat, MD, PhD Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin
Suma Shah, MD Director, MS & Neuroimmunology Fellowship, Duke University School of Medicine
S. Mitchell Freedman, MD FAAN Adjunct Professor of Neurology, University of North Carolina-Chapel Hill
Key Learning Objectives
Virtual patient visits during COVID-19 when treating MS
Changing barriers to treating MS
Evolution of monitoring safety and efficacy of therapy